356. Psilocybin Therapy is Associated With Decreases in Markers of Mitochondrial Stress and Inflammation in an Open-Label Clinical Trial of Parkinson’s Disease

Post time 1 hour(s) ago

journal：Biological Psychiatry

Authors：Ellen Bradley; D Parker Kelley; Martin Picard; Balazs Szigeti; Kimberly Sakai; Gisele Fernandes; Jill Ostrem; Caroline Tanner; Patrick Finley; Connie Ludwig; Katiah Llerena; Zach Busby; Amber McKernan; Jose Rafael Zuzuarregui; Meredith Bock; Aliss Wang; Andrew Penn; Josh Woolley; Aoife O'Donovan

Published date：2026-5-

DOI：10.1016/j.biopsych.2026.03.590

PDF link：https://www.sciencedirect.com/sc ... 006322326007055/pdf

Article link：https://doi.org/10.1016/j.biopsych.2026.03.590

Article Source：Elsevier BV。

Remark：

Post time Half hour(s) ago

: Waiting for confirmation
If the PDF has not been accepted after 72 hours, the system will automatically adopt it.

[Elsevier] 356. Psilocybin Therapy is Associated With Decreases in Markers of Mitochondrial Stress and Inflammation in an Open-Label Clinical Trial of Parkinson’s Disease

Same Category

Latest Reply

Announcement

Daily Top Contributors

[Elsevier] 356. Psilocybin Therapy is Associated With Decreases in Markers of Mitochondrial Stress and Inflammation in an Open-Label Clinical Trial of Parkinson’s Disease Copy

Same Category

Latest Reply

Announcement

Daily Top Contributors

[Elsevier] 356. Psilocybin Therapy is Associated With Decreases in Markers of Mitochondrial Stress and Inflammation in an Open-Label Clinical Trial of Parkinson’s Disease